The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion
Background: Pre-clinical research with multi-potent adult progenitor cells (MAPC® cells, Multistem, Athersys Inc., Cleveland, Ohio) suggests their potential as an anti-inflammatory and immunomodulatory therapy in organ transplantation. Normothermic machine perfusion of the liver (NMP-L) has been pro...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.01226/full |
id |
doaj-b3453b05dc9c4bec9a2bc4b80c5ab1ad |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Richard W. Laing Richard W. Laing Samantha Stubblefield Lorraine Wallace Valerie D. Roobrouck Ricky H. Bhogal Ricky H. Bhogal Andrea Schlegel Yuri L. Boteon Yuri L. Boteon Gary M. Reynolds Anthony E. Ting Darius F. Mirza Darius F. Mirza Philip N. Newsome Philip N. Newsome Hynek Mergental Hynek Mergental Simon C. Afford Simon C. Afford |
spellingShingle |
Richard W. Laing Richard W. Laing Samantha Stubblefield Lorraine Wallace Valerie D. Roobrouck Ricky H. Bhogal Ricky H. Bhogal Andrea Schlegel Yuri L. Boteon Yuri L. Boteon Gary M. Reynolds Anthony E. Ting Darius F. Mirza Darius F. Mirza Philip N. Newsome Philip N. Newsome Hynek Mergental Hynek Mergental Simon C. Afford Simon C. Afford The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion Frontiers in Immunology liver transplantation organ preservation organ donation mesenchymal progenitor cells machine perfusion stem cell therapy |
author_facet |
Richard W. Laing Richard W. Laing Samantha Stubblefield Lorraine Wallace Valerie D. Roobrouck Ricky H. Bhogal Ricky H. Bhogal Andrea Schlegel Yuri L. Boteon Yuri L. Boteon Gary M. Reynolds Anthony E. Ting Darius F. Mirza Darius F. Mirza Philip N. Newsome Philip N. Newsome Hynek Mergental Hynek Mergental Simon C. Afford Simon C. Afford |
author_sort |
Richard W. Laing |
title |
The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion |
title_short |
The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion |
title_full |
The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion |
title_fullStr |
The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion |
title_full_unstemmed |
The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion |
title_sort |
delivery of multipotent adult progenitor cells to extended criteria human donor livers using normothermic machine perfusion |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2020-06-01 |
description |
Background: Pre-clinical research with multi-potent adult progenitor cells (MAPC® cells, Multistem, Athersys Inc., Cleveland, Ohio) suggests their potential as an anti-inflammatory and immunomodulatory therapy in organ transplantation. Normothermic machine perfusion of the liver (NMP-L) has been proposed as a way of introducing therapeutic agents into the donor organ. Delivery of cellular therapy to human donor livers using this technique has not yet been described in the literature. The primary objectives of this study were to develop a technique for delivering cellular therapy to human donor livers using NMP-L and demonstrate engraftment.Methods: Six discarded human livers were perfused for 6 h at 37°C using the Liver Assist (Organ Assist, Groningen). 50 × 106 CMPTX-labeled MAPC cells were infused directly into the right lobe via the hepatic artery (HA, n = 3) or portal vein (PV, n = 3) over 20 min at different time points during the perfusion. Perfusion parameters were recorded and central and peripheral biopsies were taken at multiple time-points from both lobes and subjected to standard histological stains and confocal microscopy. Perfusate was analyzed using a 35-plex multiplex assay and proteomic analysis.Results: There was no detrimental effect on perfusion flow parameters on infusion of MAPC cells by either route. Three out of six livers met established criteria for organ viability. Confocal microscopy demonstrated engraftment of MAPC cells across vascular endothelium when perfused via the artery. 35-plex multiplex analysis of perfusate yielded 13 positive targets, 9 of which appeared to be related to the infusion of MAPC cells (including Interleukin's 1b, 4, 5, 6, 8, 10, MCP-1, GM-CSF, SDF-1a). Proteomic analysis revealed 295 unique proteins in the perfusate from time-points following the infusion of cellular therapy, many of which have strong links to MAPC cells and mesenchymal stem cells in the literature. Functional enrichment analysis demonstrated their immunomodulatory potential.Conclusion: We have demonstrated that cells can be delivered directly to the target organ, prior to host immune cell population exposure and without compromising the perfusion. Transendothelial migration occurs following arterial infusion. MAPC cells appear to secrete a host of soluble factors that would have anti-inflammatory and immunomodulatory benefits in a human model of liver transplantation. |
topic |
liver transplantation organ preservation organ donation mesenchymal progenitor cells machine perfusion stem cell therapy |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2020.01226/full |
work_keys_str_mv |
AT richardwlaing thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT richardwlaing thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT samanthastubblefield thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT lorrainewallace thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT valeriedroobrouck thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT rickyhbhogal thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT rickyhbhogal thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT andreaschlegel thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT yurilboteon thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT yurilboteon thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT garymreynolds thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT anthonyeting thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT dariusfmirza thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT dariusfmirza thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT philipnnewsome thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT philipnnewsome thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT hynekmergental thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT hynekmergental thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT simoncafford thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT simoncafford thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT richardwlaing deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT richardwlaing deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT samanthastubblefield deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT lorrainewallace deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT valeriedroobrouck deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT rickyhbhogal deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT rickyhbhogal deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT andreaschlegel deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT yurilboteon deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT yurilboteon deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT garymreynolds deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT anthonyeting deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT dariusfmirza deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT dariusfmirza deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT philipnnewsome deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT philipnnewsome deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT hynekmergental deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT hynekmergental deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT simoncafford deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion AT simoncafford deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion |
_version_ |
1724651153498570752 |
spelling |
doaj-b3453b05dc9c4bec9a2bc4b80c5ab1ad2020-11-25T03:12:10ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-06-011110.3389/fimmu.2020.01226537048The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine PerfusionRichard W. Laing0Richard W. Laing1Samantha Stubblefield2Lorraine Wallace3Valerie D. Roobrouck4Ricky H. Bhogal5Ricky H. Bhogal6Andrea Schlegel7Yuri L. Boteon8Yuri L. Boteon9Gary M. Reynolds10Anthony E. Ting11Darius F. Mirza12Darius F. Mirza13Philip N. Newsome14Philip N. Newsome15Hynek Mergental16Hynek Mergental17Simon C. Afford18Simon C. Afford19NIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomAthersys Inc., Cleveland, OH, United StatesNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomReGenesys BVBA, Leuven, BelgiumNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomAthersys Inc., Cleveland, OH, United StatesNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomBackground: Pre-clinical research with multi-potent adult progenitor cells (MAPC® cells, Multistem, Athersys Inc., Cleveland, Ohio) suggests their potential as an anti-inflammatory and immunomodulatory therapy in organ transplantation. Normothermic machine perfusion of the liver (NMP-L) has been proposed as a way of introducing therapeutic agents into the donor organ. Delivery of cellular therapy to human donor livers using this technique has not yet been described in the literature. The primary objectives of this study were to develop a technique for delivering cellular therapy to human donor livers using NMP-L and demonstrate engraftment.Methods: Six discarded human livers were perfused for 6 h at 37°C using the Liver Assist (Organ Assist, Groningen). 50 × 106 CMPTX-labeled MAPC cells were infused directly into the right lobe via the hepatic artery (HA, n = 3) or portal vein (PV, n = 3) over 20 min at different time points during the perfusion. Perfusion parameters were recorded and central and peripheral biopsies were taken at multiple time-points from both lobes and subjected to standard histological stains and confocal microscopy. Perfusate was analyzed using a 35-plex multiplex assay and proteomic analysis.Results: There was no detrimental effect on perfusion flow parameters on infusion of MAPC cells by either route. Three out of six livers met established criteria for organ viability. Confocal microscopy demonstrated engraftment of MAPC cells across vascular endothelium when perfused via the artery. 35-plex multiplex analysis of perfusate yielded 13 positive targets, 9 of which appeared to be related to the infusion of MAPC cells (including Interleukin's 1b, 4, 5, 6, 8, 10, MCP-1, GM-CSF, SDF-1a). Proteomic analysis revealed 295 unique proteins in the perfusate from time-points following the infusion of cellular therapy, many of which have strong links to MAPC cells and mesenchymal stem cells in the literature. Functional enrichment analysis demonstrated their immunomodulatory potential.Conclusion: We have demonstrated that cells can be delivered directly to the target organ, prior to host immune cell population exposure and without compromising the perfusion. Transendothelial migration occurs following arterial infusion. MAPC cells appear to secrete a host of soluble factors that would have anti-inflammatory and immunomodulatory benefits in a human model of liver transplantation.https://www.frontiersin.org/article/10.3389/fimmu.2020.01226/fullliver transplantationorgan preservationorgan donationmesenchymal progenitor cellsmachine perfusionstem cell therapy |